Choosing the right DOAC is not just about preventing clots, it is about maximizing safety for every patient. In this episode, we unpack the latest evidence on direct oral anticoagulants, including the practice changing COBRRA trial comparing apixaban and rivaroxaban. Discover why similar effectiveness can come with very different bleeding risks, and how that should shape your prescribing decisions. We also explore high yield clinical pearls, from taking rivaroxaban with food to renal dosing and the unique properties of each DOAC. Whether you are in practice or still learning, this episode will help you confidently navigate DOAC selection in real world care.